Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada

 Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada

Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada

Shots:

  • The safety & efficacy of Emgality (120mg after an initial loading dose of 240mg) is evaluated in three P-III studies EVOLVE-1, EVOlVE-2 and REGAIN study in comparison with PBO in 2500+ patients with episodic & chronic migraine respectively
  • Collective Results: mean change from baseline (-4.7, -4.3 & -4.8 vs -2.8, -2.3 &-2.7 days); Up to 3 in 5 patients achieved 50% reduction in migraine headache days (MHDs)/mos. (62%,59% vs 39%, 36%); >1 in 3 patients achieved 75% reduction in MHDs (39%,34% vs 19%,18%); Up to 1 in 7 patients achieved a 100% reduction in MHDs (16%, 12% vs 6%,6%);  50% reduction in MHDs (28% vs 15%) respectively
  • Emgality (SC) is a mAb targeting CGRP and inhibits its biological activity and is indicated for the prevention of migraine in adults with at least 4 migraine days per month in Canada

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharma Compass

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post